HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy

被引:14
作者
Notsuda, Hirotsugu [1 ,2 ]
Bradbury, Penelope A. [3 ,4 ]
Tsao, Ming-Sound [1 ,2 ]
机构
[1] Univ Toronto, Princess Margaret Canc Ctr, Dept Pathol, Univ Hlth Network, Toronto, ON, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
KINASE DOMAIN; DRUGS;
D O I
10.1016/j.jtho.2017.01.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:422 / 424
页数:3
相关论文
共 12 条
[11]  
Ross, 1998, Oncologist, V3, P237
[12]   HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors [J].
Wang, Shizhen Emily ;
Narasanna, Archana ;
Perez-Torres, Marianela ;
Xiang, Bin ;
Wu, Frederick Y. ;
Yang, Seungchan ;
Carpenter, Graham ;
Gazdar, Adi F. ;
Muthuswamy, Senthil K. ;
Arteaga, Carlos L. .
CANCER CELL, 2006, 10 (01) :25-38